Physician profile
Amy Ly
NPI 1447519970
$6,970.72
in general payments reported to CMS, 2019-2025
30 companies · $233 in 2025
The $233 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,227 · 2020: $990 · 2021: $1,381 · 2022: $1,901 · 2023: $892 · 2024: $347 · 2025: $233.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,471.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,471.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,390.01 | 2021-2025 | |
| Amgen INC. | $670.82 | 2019-2023 | Aimovig |
| Eisai INC. | $649.77 | 2019-2023 | |
| Lilly USA, LLC | $618.98 | 2019-2024 | Emgality, Amyvid |
| Teva Pharmaceuticals USA, INC. | $575.06 | 2019-2023 | Ajovy, Austedo |
| Upsher-Smith Laboratories LLC | $406.19 | 2019-2023 | |
| Allergan, INC. | $382.36 | 2020-2022 | |
| Amneal Pharmaceuticals LLC | $285.59 | 2019-2024 | Rytary |
| Biohaven Pharmaceutical Holding Company LTD. | $280.41 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $257.17 | 2020-2021 | |
| Pfizer INC. | $188.87 | 2021-2024 | |
| Sunovion Pharmaceuticals INC. | $173.70 | 2020-2021 | |
| Genzyme Corporation | $148.28 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $119.26 | 2019-2020 | |
| Celgene Corporation | $117.11 | 2020-2023 | Zeposia |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $109.58 | 2019-2021 | |
| Ucb, INC. | $97.45 | 2020-2022 | |
| Genentech USA, INC. | $72.28 | 2019-2022 | |
| Lundbeck LLC | $62.96 | 2022-2023 | Vyepti |
| E.R. Squibb & Sons, L.L.C. | $59.64 | 2020-2021 | |
| Averitas Pharma INC. | $58.42 | 2023 | Qutenza |
| Tanabe Pharma America, INC. | $55.66 | 2019-2021 | |
| Adamas Pharmaceuticals, INC. | $38.35 | 2021 | |
| Sk Life Science, INC. | $30.95 | 2020-2022 | |
| Supernus Pharmaceuticals, INC. | $29.54 | 2020-2022 | |
| Horizon Therapeutics Plc | $26.15 | 2022 | |
| Ge Healthcare | $19.24 | 2021 | |
| Biogen, INC. | $18.21 | 2020 | |
| Neurelis, INC. | $15.07 | 2020 | |
| Alexion Pharmaceuticals, INC. | $13.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Ly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.